Aging HIV Population Should be Monitored for Diabetes

As the population of individuals with HIV is living longer, the development of diabetes mellitus has become a particular concern. Although antiretroviral therapy (ART) has led to significantly longer life expectancies among individuals with HIV, this, in turn, has contributed to the likelihood that these individuals will develop age-related comorbidities at earlier ages. Additionally, research has shown that the use of older antiretrovirals, which were associated with fat atropine, visceral fat accumulation, and metabolic complications, are contributing factors to the development of diabetes in this population.

Recently, investigators from a number of facilities located in Vancouver, British Columbia, Canada published a study in BMJ Open Diabetes Research & Care that documents higher incidences of diabetes in older adults with HIV. They also established a correlation between advanced infection, use of older antiretrovirals, and the development of diabetes.

For the study, a total of 1065 individuals with HIV were followed for approximately 13 years. The majority of patients (80%) were male and 43% had hepatitis C coinfection. Approximately 38% were injection drug users. Of note, the median body mass index for participants was 24 kg/m2, which was considered normal to low compared with the general population. All participants were 50 years of age or older.

For more information, please visit ContagionLive.com.


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

The Working Group examined the insulin supply chain and the factors that impact the costs of and access to insulin products.
Allergan announced positive topline results from CGP-MD-01, a phase 2b/3 clinical trial of atogepant.
Patients with both private and public insurers face high denial rates across the United States for life-saving hepatitis C drugs, despite changes in restrictions and increased price competition.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$